ArticleMicrobiology and immunology2025
Circulating Cell-Free DNA of Bovine Leukemia Virus: A Promising Biomarker for Enzootic Bovine Leukosis.
Article in Microbiology and immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- TRIM24 stabilizes the p110 CUX1 oncoprotein via USP10 to promote chemoresistance in acute myeloid leukemia.Journal of translational medicine · 2026Article
- TiSMeD: A tissue-specific methylation and expression database for biomarker and translational applications.Molecular therapy. Nucleic acids · 2026Article
- Proteomics in bone malignancies: from bulk profiling to single-cell and ultra-low-input technologies.Journal of translational medicine · 2026Review
- Integrating biomarkers and artificial intelligence for precision diagnostics in cattle health and herd management: a review.Veterinary research communications · 2026Review
- Engineered soluble truncated envelope proteins block bovine leukemia virus infection.Virus research · 2026Article
- SCMO: a deep learning model integrating the single-cell resolution TME ecosystem and multi-omics for survival prediction in CRC patients.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bovine leukemia virus (BLV) causes Enzootic bovine leukosis (EBL) in approximately 1%-5% of infected cattle after a long latent period. Few biomarkers effectively distinguish non-EBL from EBL cattle. Given the rapid turnover of tumor cells, we hypothesized that cell-free DNA (cfDNA) in plasma could serve as a more effective biomarker for EBL diagnosis. We measured the proviral load (PVL) in whole blood and plasma by quantitative PCR targeting LTR and pol. Consistent with previous reports, PVL levels in whole blood in EBL cattle were generally higher than those in non-EBL with some overlap between these two groups. In contrast, PVL in plasma clearly distinguished non-EBL from EBL ones. The receiver operating characteristic analysis showed plasma PVL perfectly discriminated EBL from non-EBL (100% sensitivity and specificity), while whole-blood PVL achieved 70% sensitivity and 30% specificity. Additionally, length of PCR products played a role in PVL detection sensitivity in plasma. We compared the complete BLV sequence between genomic DNA from lymphoma tissue and cfDNA in plasma and found that the predominant BLV sequences were highly similar between them. By assessing the major tumor clone burden based on unique integration sites, we found that BLV cfDNA derived more from tumor clones in the tissues than from peripheral blood mononuclear cells (PBMCs). These data support the idea that BLV in cfDNA primarily originates from tumor cells in EBL cattle. These findings demonstrated that cfDNA could be a better indicator for EBL diagnosis, improving early detection and more timely intervention to reduce the economic loss in the meat and dairy industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.